U.S. patent application number 17/192155 was filed with the patent office on 2021-10-28 for method of making solanaceae fruit extracts.
This patent application is currently assigned to Provexis Natural Products Limited. The applicant listed for this patent is Provexis Natural Products Limited. Invention is credited to Niamh O'Kennedy.
Application Number | 20210330732 17/192155 |
Document ID | / |
Family ID | 1000005697389 |
Filed Date | 2021-10-28 |
United States Patent
Application |
20210330732 |
Kind Code |
A1 |
O'Kennedy; Niamh |
October 28, 2021 |
METHOD OF MAKING SOLANACEAE FRUIT EXTRACTS
Abstract
Provided are methods of making an extract of fruit of the
Solanaceae family wherein fruit is processed to optimise the
platelet aggregation inhibiting activity of the extract. The
methods involve preparing a start mix of homogenised fruit;
separating a water soluble fraction from fruit solids; filtration
of the water soluble fraction; and concentration of active agents
in the filtration permeate. The invention also provides fruit
extracts manufactured by such methods, and also fruit extracts
containing glycosylated phenolic acid or a phenolic ester, or
derivatives thereof; a glycosylated flavonoid; and a nucleoside.
The extracts of the invention are useful as medicaments for the
treatment or prevention of a medical condition characterised by
inappropriate platelet aggregation. In particular, the medicaments
may be of use in maintaining heart health by reducing platelet
aggregation; benefiting the circulation; and/or normalizing or
otherwise benefiting blood flow.
Inventors: |
O'Kennedy; Niamh; (Reading,
GB) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Provexis Natural Products Limited |
Reading |
|
GB |
|
|
Assignee: |
Provexis Natural Products
Limited
Reading
GB
|
Family ID: |
1000005697389 |
Appl. No.: |
17/192155 |
Filed: |
March 4, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15866900 |
Jan 10, 2018 |
10973865 |
|
|
17192155 |
|
|
|
|
14030533 |
Sep 18, 2013 |
|
|
|
15866900 |
|
|
|
|
13124512 |
Apr 15, 2011 |
|
|
|
PCT/GB2009/002593 |
Nov 2, 2009 |
|
|
|
14030533 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 36/81 20130101;
A61K 31/7064 20130101; A61K 31/7048 20130101 |
International
Class: |
A61K 36/81 20060101
A61K036/81; A61K 31/7048 20060101 A61K031/7048; A61K 31/7064
20060101 A61K031/7064 |
Foreign Application Data
Date |
Code |
Application Number |
Oct 31, 2008 |
GB |
0819959.8 |
Claims
1-23. (canceled)
24. A substantially lycopene-free extract of fruit of the
Solanaceae family comprising: (a) glycosylated phenolic acid or a
phenolic ester, or derivatives thereof; (b) a glycosylated
flavonoid; and (c) a nucleoside; wherein the extract contains
<1% sugars and contains >95% of the bioactive components (a),
(b) and (c) that are contained in a start mix from which the
extract is prepared.
25. The substantially lycopene-free extract of claim 24, further
comprising an excipient.
26. The substantially lycopene-free extract of claim 24 wherein the
glycosylated phenolic acid or a phenolic ester is a glycosylated
cinnamic acid or derivative thereof and may be selected from the
group comprising Caffeoyl-4-O-quinic acid, Caffeoyl-4-O-glucoside,
Coumaroyl-4-O-glycoside (gluc/gal) and Coumaroyl-4-O-glycoside
(disaccharide).
27. The substantially lycopene-free extract of claim 24 wherein the
glycosylated phenolic acid or a phenolic ester is selected from:
Caffeic acid glucoside; p-Coumaric acid hexose/dihydrokaempferol
hexose; Ferulic acid glycoside; and a p-Coumaric acid
derivative.
28. The substantially lycopene-free extract of claim 24 wherein the
glycosylated flavonoid is Quercetin-3-O-glucoside or Rutin.
29. The substantially lycopene-free extract of claim 24 wherein the
nucleoside is selected from the group comprising AMP, Uridine,
Adenosine, Guanosine or GMP.
30. The substantially lycopene-free extract of claim 24 formulated
as a solution, suspension, syrup, tablet, capsule or lozenge.
31. A dosage form of the substantially lycopene-free extract of
claim 24 comprising 10 -500 mg dry weight of the extract.
32. The dosage form of claim 31, further comprising an
excipient.
33. The dosage form of claim 31, comprising between about 85 mgs
and about 150 mg dry weight of the extract.
34. A method for treating or inhibiting a medical condition
characterised by inappropriate platelet aggregation comprising
administering a substantially lycopene-free extract of tomato fruit
to a subject in need thereof, wherein the substantially
lycopene-free extract comprises: (a) glycosylated phenolic acid or
a phenolic ester, or derivatives thereof; (b) a glycosylated
flavonoid; and (c) a nucleoside; and wherein the substantially
lycopene-free extract contains <1% sugars and contains >95%
of the bioactive components (a), (b) and (c) that are contained in
a tomato fruit start mix from which the extract is prepared.
35. The method of claim 34, wherein the treatment or inhibition of
the medical condition characterised by inappropriate platelet
aggregation is for a purpose selected from the group consisting of:
maintaining heart health by reducing platelet aggregation;
benefiting the circulation; and normalizing or otherwise benefiting
blood flow.
36. The method of claim 35, wherein the substantially lycopene-free
extract: (a) reduces occurrence of a hypercoagulable or
prothrombotic state; (b) reduce development of atherosclerosis; (c)
reduces development of coronary disease; (d) reduces development of
restenosis following angioplasty and bypass procedures; (e) treats
coronary disease resulting from thrombo-embolic disorders; reduces
the risk of deep vein thrombosis; (g) benefits the circulation to
maintain good circulatory health; or (h) maintains healthy blood
flow in the cardiovascular system.
37. An substantially lycopene free extract of fruit of the
Solanaceae family having optimized platelet aggregation inhibiting
activity made by a process, comprising: (a) preparing a start mix
of homogenized fruit, wherein the start mix has a pH that does not
exceed 5.5 and the start mix is held at a temperature that does not
exceed 35.degree. C.; (b) separating a water soluble fraction from
the start mix from insoluble solids of the start mix, wherein the
water soluble fraction is obtained without raising the temperature
of the fraction above 60.degree. C.; (c) filtering the water
soluble fraction; (d) removing free sugars from the filtered water
soluble fraction with a food grade resin, wherein the resin adsorbs
components from the fraction but does not adsorb free sugars,
organic acids and salts, wherein the adsorbed components are
recovered from the resin by elution with an ethanol/water mixture
to provide a solution, and wherein ethanol is removed from the
solution by evaporation under reduced pressure or by reverse
osmosis; and (e) concentrating the solution to provide the extract
of fruit of the Solanaceae family, wherein the extract is a
concentrated aqueous solution containing <1% sugar and >95%
of bioactive components contained in the start mix.
38. The substantially lycopene free extract of claim 37, wherein
the browning index of the start mix does not exceed 0.4 AU at 4%
solids.
39. The substantially lycopene free extract of claim 37, wherein
the sugars are removed by resin-mediated separation.
40. The substantially lycopene free extract of claim 37, wherein
the extract is further processed into a powder.
41. The substantially lycopene free extract of claim 37, wherein
the start mix is diluted and comprises less than 33% solids.
42. The substantially lycopene free extract of claim 37, further
comprising an excipient.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 15/866,900 filed Jan. 10, 2018, which is a
continuation of application Ser. No. 14/030,533, now abandoned,
filed Sep. 18, 2013, which is a continuation of application Ser.
No. 13/124,512, now abandoned, filed Apr. 15, 2011, which is the
National Phase of International Application PCT/GB2009/002593,
filed Nov. 2, 2009 which designated the U.S. and that International
Application was published under PCT Article 21(2) in English. This
application also includes a claim of priority under 35 U.S.C.
.sctn. 119(a) and .sctn. 365(b) to British patent application No.
GB 0819959.8, filed Oct. 31, 2008.
[0002] The present invention relates to a fruit extract that
prevents platelet aggregation and is useful as an antithrombotic
agent and methods of making such extracts.
[0003] It is well established that consumption of fruits and
vegetables is an important preventative measure by which the risk
of cardiovascular diseases can be reduced. Accordingly considerable
effort has been expended in an attempt to identify compounds
derived from fruits and vegetables that have a role in the
prevention of heart disease.
[0004] Particular interest has been shown in agents that inhibit
platelet aggregation. When platelets aggregate within the
circulatory system, thrombi are formed which are large enough to
block blood vessels. However before full aggregation takes place,
platelets can circulate in an activated condition. When in this
state, platelet stickiness is greatly increased, and they can stick
to each other, to other blood cells, or to components of the blood
such as lipid-rich chylomicrons. This causes micro-aggregates to
form, and lowers the fluidity of the blood, affecting blood flow
locally, and the circulation systemically. Reducing platelet
aggregability helps to maintain the blood in a fluid and
low-coagulable state. This helps to normalize blood flow, by
preventing micro-aggregates from forming within the circulation,
and by preventing the adherence of platelets to blood vessel walls
or fatty plaques.
[0005] In the light of this will be recognized that agents able to
inhibit platelet aggregation are of use in preventing coronary
disease, for example myocardial infarctions and stroke and in
preventing further thrombo-embolic events in patients who have
suffered myocardial infarction, stroke or unstable angina. In
addition, such agents may be of use in preventing restenosis
following angioplasty and bypass procedures. Moreover, these agents
may be of use in the treatment of coronary disease resulting from
thrombo-embolic disorders such as myocardial infarction in
conjunction with thrombolytic therapy.
[0006] There are many known anti-platelet-aggregation agents that
act at different stages of platelet production and action. Aspirin
(acetylsalicylic acid) is the most widely used and studied.
Dipyridamole and ticlopidine have also been used. Aspirin's
antiplatelet activity is due to irreversible inhibition of platelet
cyclo-oxygenase, thus preventing the synthesis of thromboxane A2, a
compound that causes platelet aggregation. Indobufen is a
reversible inhibitor of platelet cyclo-oxygenase. Some compounds
are direct inhibitors of thromboxane A2 synthase, for example
pirmagrel, or act as antagonists at thromboxane receptors, for
example sulotroban.
[0007] International Patent application WO 99/55350 discloses that
water-soluble extracts from a number of fruits exhibit an ability
to inhibit platelet aggregation. It was considered surprising that
anti-platelet-aggregation activity was found to be water soluble
because, in contrast, active extracts known to the art at that time
were lipid soluble compounds (e.g. lycopene). These water-soluble
extracts were found to have significant efficacy for preventing or
reducing platelet aggregation and have been marketed, with Food
Standards Agency approval in Europe, as a nutritional supplement
with health benefits.
[0008] The active component of the WO 99/55350 fruit extract was
analysed by mass spectroscopy (MS) and nuclear magnetic resonance
(NMR) spectroscopy and found to contain a mixture of nucleosides
having platelet aggregation inhibiting activity.
[0009] The present invention is based upon the inventor's
realisation that nucleosides, within water-soluble fruit extracts,
may not be the only compounds within such extracts that prevent
anti-platelet aggregation. They therefore exerted considerable
effort to further fractionate and characterize the active agents
within water-soluble extracts described in WO 99/55350 in an
attempt to improve the efficacy of such extracts for inhibiting
platelet aggregation and develop new methods of processing fruit
for such a use.
[0010] It has now been found that fruits of the Solanaceae family,
may be processed in ways that result in water-soluble extracts that
have an optimised beneficial effect on platelet aggregation. This
new knowledge has enabled the inventors to develop new fruit
extracts, and methods of making the same, with efficacy for
inhibiting platelet aggregation.
[0011] Thus according to a first aspect of the invention there is
provided a method of making an extract of fruit of the Solanaceae
family wherein fruit is processed to optimise the platelet
aggregation inhibiting activity of the extract comprising the steps
of: [0012] (a) Preparing a start mix of homogenised fruit; [0013]
(b) Separating a water-soluble fraction from fruit solids; [0014]
(c) filtration of the water-soluble fraction; and [0015] (d)
concentration of active agents in the filtration permeate
[0016] The inventors decided to analyse the active compounds in the
fruit extracts described in WO 99/55350 (see Example 1). The
inventors were surprised to find that a number of compounds, found
naturally in plants, were effective for inhibiting platelet
aggregation. This lead them to realise that the methods described
in WO 99/55350 may be adapted to develop methods that will result
in extracts in which the content of such active agents is
maintained (i.e. minimal amounts of the active compound are lost
during the processing of the fruit) or the active agents are
actually enriched in the production of a fruit extract. After much
trial and error they established that the steps according to the
method of the first aspect of the invention results in fruit
extracts that are effective for reducing platelet aggregation and
comprise a number of active, water soluble compounds found in the
fruit.
[0017] (a) Preparing a Start Mix
[0018] The flesh of whole fruit, preferably tomatoes, is
homogenised, with or without the skin of the fruit to form a
paste.
[0019] Alternatively, commercially available tomato pastes may be
used as the starting material for the preparation of the start mix.
Where the starting material for the preparation of the extracts is
a tomato paste, it is preferably one that has been produced by
means of a "cold-break" process rather than a "hot-break" process.
The terms "cold-break" and "hot-break" are well known in the field
of tomato processing and commercially available tomato pastes are
typically sold as either hot-break or cold-break pastes. Cold-break
pastes can be prepared by a process involving homogenisation of the
tomato followed by a thermal processing step in which the tomatoes
are heated to temperatures of no more than about 60.degree. C., in
contrast to hot-break pastes where the homogenised tomatoes are
subjected to thermal processing at temperatures of about 95.degree.
C., see for example, Anthon et al., J. Agric. Food Chem. 2002, 50,
6153-6159.
[0020] The thickness of such pastes (whether from fresh fruit or a
commercially available paste) should be adjusted by diluting with
water or an aqueous solution (preferably demineralised water) to
form a "start mix". The inventors have found that optimal activity
is achieved in the final fruit extract if the start mix is diluted
such that it contains less than 33% solids and more preferably less
than 20% solids. In one preferred embodiment of the invention the
start mix comprises between about 10 and 15% solids (e.g. 13%
solids).
[0021] The inventors have found that the holding temperature of the
start mix can have a significant effect on the activity of the
extract. It is therefore preferred that the holding temperature
does not exceed 35.degree. C. and more preferably does not exceed
30.degree. C.
[0022] The inventors have also found that the pH of the start mix
also impacts on the activity of the extract prepared according to
the method of the invention. The pH of the mix should be acidic;
preferably less than pH 5.5 and in a preferred embodiment the pH
should not rise above 4.2. Adjustments to pH, if required, may be
made by addition of citric acid.
[0023] Furthermore the inventors have found that the browning index
of the start mix should also be controlled to optimise activity of
the finial extract. Accordingly the browning index of the start
mix, defined as the absorbance of the soluble portion at 420 nm,
preferably does not exceed 0.4 AU at 4% solids. Browning index is
an index of visible browning caused by formation of melanoidins
(polymeric conjugates of variable composition, based on sugars and
amino acids) and may be measured by centrifuging a 50 mL sample of
the start mix at 3500 rpm for 10 minutes at room temperature,
removing a portion of the supernatant, diluting it to 4% solids as
measured by refractometer, and measuring the absorbance of this
solution at 420 nm in a spectrophotometer.
[0024] The inventors have found that fruit extracts according to
the method of the invention have improved anti-aggregation activity
if at least one of the temperature, pH and browning index are
controlled in the start mix as discussed above. It is preferred
that at least two of these control steps (e.g. temperature and pH;
or temperature and browning index) are controlled and more
preferred that the temperature, pH and Browning index are
controlled as discussed above.
[0025] It is most preferred that the start mix is maintained at a
temperature that is no higher than 30.degree. C.; at a pH of less
than 4.2 and with a browning index that does not exceed 0.4 AU.
[0026] (b) Separating a Water-Soluble Fraction from Fruit
Solids.
[0027] Water-insoluble solids may be removed from a water-soluble
fraction by using a number of standard techniques.
[0028] It is preferred that this step in the methodology removes
large-sized (i.e. particle size >500.mu.) water insoluble solids
from the start mix.
[0029] Such solids may be removed by use of: [0030] (a) a decanter
(e.g. a Westfalia GEA decanter); [0031] (b) a centrifugal
separation step (e.g. a rotating disc centrifuge); or [0032] (c) a
separator containing size-adjustable nozzles (e.g. a Westfalia
MSB-15 separator, using a mixture of blanks and nozzles sized
0.45).
[0033] Alternatively the solids may be allowed to settle and the
water-soluble fraction simply decanted manually.
[0034] Whichever method is used, the inventors have found that for
retention of optimal bioactivity in the water-soluble fraction, the
operating temperatures should not exceed 60.degree. C. Furthermore
it is preferred that the flow rate through the equipment must be
such that exposure to this 60.degree. C. temperature does not occur
for longer than 60 seconds.
[0035] The resulting water-soluble fraction should ideally be
cooled after the separation step. When the fraction is to be stored
it is preferred that, following separation, it is immediately
cooled to <8.degree. C.
[0036] In preferred embodiments of step (c) of the method of the
invention a decanter may be used, with running temperatures of
40-45.degree. C.
[0037] Optionally the separation step may be followed by a second
clarification step (e.g. using an Alfa Lavaal Clarifier) to produce
a clarified water-soluble fraction where all remaining insoluble
material has a particle size <500.mu. and spin-down solids (i.e.
material which is visibly precipitated by centrifugation at 3500
rpm for 10 minutes at room temperature) comprise <1% of the
fraction by volume.
[0038] The inventors have found that the final product retains the
maximum active component concentration if the clarified fraction
(however produced) contains less than 10% total solids and more
preferably about 8% solids or less.
[0039] (c) Filtration of the Water-Soluble Fraction
[0040] To remove very fine particulate matter (<500.mu.) (e.g.
protein and large polymeric material such as some pectins), the
water-soluble fraction should then be filtered and the permeate
retained.
[0041] Filtration may be accomplished in a single stage, or in a
series of filtration steps, starting with a relatively coarse
filtration step to remove larger particles of tomato skin and/or
other water-insoluble fragments of tomato flesh. Further filtration
steps may then be effected to give a substantially clear solution,
e.g. a solution that will pass through a 0.2.mu. filter without
loss of solids.
[0042] In a preferred embodiment step (c) of the method of the
invention comprises a microfiltration step using a filtration unit
with ceramic membrane filters (e.g. a Tetra Alcross
cross-filtration MF unit equipped with ceramic membrane filters
(e.g. Pall Membralox P19-30 multi-element units)). Spiral-wound
membranes may also be used as an alternative to ceramic
membranes.
[0043] Ultrafiltration may also be used as an alternative to
microfiltration. A range of pore sizes is acceptable, e.g. 1.4.mu.,
0.1.mu.; but the inventors have found that maximum enrichment of
the filtration permeate with bioactive components (i.e. minimum
losses of bioactive components and maximum exclusion of
non-bioactive components) occurs when pore sizes of 0.1.mu. are
used.
[0044] In order to retain optimal bioactivity, temperatures should
not rise above 35.degree. C. during this filtration step, and the
filtration permeate should be immediately cooled to <8.degree.
C. after exiting the filtration membrane. The browning index of the
final permeate should not exceed 0.4 AU.
[0045] The inventors have found that maximum recovery of bioactive
components, and enrichment of the filtration permeate in bioactive
components (relative to the unfiltered material), occurs when the
starting unfiltered material contains <10% solids, and when the
final permeate contains approximately 7% solids and has a browning
index <0.4 AU.
[0046] Removal of the solids according to steps (a) to (c) has the
effect of removing fragments of skin and seeds, large molecular
weight proteins and pectins, and carotenoids such as lycopene/other
lipids which are stabilised in droplets within the aqueous solution
by the presence of pectins and proteins. Thus, the methods provide
ways of preparing tomato extracts that are water soluble extracts
and are also substantially free of lycopene.
[0047] The methods described, in particular the careful control of
the length of exposure to temperatures >35.degree. C.
(preferably >30.degree. C.), also ensure that the lycopene-free
water-soluble extracts prepared have not been subject to
degradative chemical reactions which result in the production of
visible browning (Maillard reactions), as demonstrated by the
browning index value of <0.4 AU. This ensures that the formation
of amino acid-sugar complexes and melanoidin polymers, which can
sequester some of the bioactive components, are kept to a minimum.
Thus the methods described result in extracts which are optimised
for bioactive component content.
[0048] In one preferred embodiment of the method of the invention,
the tomato extract is a water-soluble extract substantially free of
lycopene and capable of passing through a 0.2.mu. filter without
loss of solids, and with a browning index value <0.4 AU.
[0049] (d) Concentration of Active Agents in the Filtration
Permeate
[0050] The aqueous filtrate is then subjected to further
concentration/fractionation steps to provide a bioactive
concentrate containing compounds responsible for inhibiting
platelet aggregation.
[0051] After much experimentation the inventors established that
the concentration steps required careful control if peak
bioactivity of the final extract was to be retained or enrichment
of bioactives is to be achieved in the final concentrated product.
The reason for this was found to be, that the progress of heat- and
pH-dependent degradative reactions is accelerated as solids
concentration increases. They therefore realised that temperature
control, and length of exposure to temperature, was more crucial
for concentrated extracts than for dilute extracts.
[0052] Several methods may be used to concentrate/enrich the
water-soluble material--provided that the temperature of the
extract is not allowed to rise such that degradation of active
agents within the extract is not allowed to rise above about
60.degree. C. for dilute fractions and below 40.degree. C. for more
concentrated samples.
[0053] Concentration using Evaporation Techniques
[0054] Evaporation of the solution under reduced pressure may be
used, under conditions where temperatures do not exceed 60.degree.
C.
[0055] Preferably, a multi-effect evaporator is used, so that
temperatures can be lowered as the liquid passes through the
evaporator, ensuring that the more concentrated material is not
exposed to temperatures >40.degree. C., whereas the more dilute
material can tolerate temperatures of up to 60.degree. C.
[0056] Using evaporation, the water-soluble extract can be
concentrated up to 70% solids, e.g. to 20% solids, or to 50%
solids, or to 65% solids. In a most preferred embodiment the final
extract comprises 60-62% solids after concentration according to
step (d).
[0057] The effect of temperature can be quantified by measuring the
browning index. Temperatures should be sufficiently low such that
the final concentrated product should not exceed 0.8 AU.
[0058] The final concentrate formed following steps (a), (b), (c)
and utilising an evaporator according to step (d) preferably has a
browning index of <0.8 AU, a pH of 4.0 -4.3 and a density of
1.15-1.20.
[0059] Concentration using Membrane Processes
[0060] Alternatively Membrane processes which allow water to pass
through the membrane while retaining all other components within
the membrane can also be used. Examples of specific techniques are
reverse osmosis, or nanofiltration. Both can be used to concentrate
the water-soluble extract to the required degree, while operating
at low temperatures (<40.degree. C.).
[0061] Drying Techniques
[0062] Drying technologies can also be used to remove water from
the water-soluble extract. Suitable drying techniques include spray
drying, with or without carrier materials (e.g. potato starch,
tapioca starch, maltodextrins); vacuum drum drying, with or without
carrier materials; or roller drying, with or without carrier
materials.
[0063] Preparation of Low Sugar Fruit Extracts
[0064] The methods described above were designed for the production
of a concentrate containing all the elements originally present in
the water-soluble extract.
[0065] In a preferred embodiment of the invention the method of the
first aspect of the invention may be adapted to result in a
concentrate that is enriched (e.g. 25-35 times) in the bioactive
components.
[0066] Enrichment of the bioactive components within the
water-soluble extract can be achieved by removing the soluble
sugars which form the largest portion of its dry matter
content.
[0067] Low sugar fruit extracts may be prepared by following steps
(a), (b) and (c) above and then employing a further step in the
methods before the final concentration step ((d) above)
[0068] Removal of the soluble sugars can be achieved by: [0069] (1)
precipitation, e.g. by adding ethanol to the solution to a final
concentration of 90%, which will result in precipitation of free
glucose, fructose and sucrose; [0070] (2) Partial removal of free
sugars by digestion, by enzymes (e.g. glucose oxidase); [0071] (3)
by microbial (bacteria or yeast) treatment; or [0072] (4) removing
free sugars from the water-soluble extract by resin-mediated
separation of the extract components
[0073] It is preferred that free sugars are removed from the
water-soluble extract by resin-mediated separation of the extract
components ((4) above). The inventors have developed a method in
which a food grade resin (Amberlite FPX66) is employed to adsorb
all the extract components, with the exception of free sugars,
organic acids, and salts. These are not adsorbed by the resin and
may be discarded after passing through. The extract components
adsorbed onto the resin, which comprise amino acids, bioactive
components, and products of browning reactions (Maillard
degradation products), are then recovered from the resin by elution
with ethanol/water mixtures, e.g. 50% ethanol, or 80% ethanol.
Ethanol may be removed from the resulting solution by evaporation
under reduced pressure (e.g. in an explosion-proof conventional
evaporator, or in a Centritherm centrifugal concentrator), or by
reverse osmosis.
[0074] After the removal of the sugars the concentration of the
product may be adjusted employing the procedures discussed in step
(d) above.
[0075] The resulting low sugar extract is preferably a concentrated
aqueous solution containing <1% sugar, and containing >95% of
the bioactive components contained in the start mix.
[0076] Fruit Extracts
[0077] The extracts prepared according to the methods of the first
aspect of the invention represent novel fruit extracts with
surprising efficacy for preventing platelet aggregation.
[0078] Therefore according to a second aspect of the invention
there is provided a fruit extract capable of inhibiting platelet
aggregation prepared according to the methods of the first aspect
of the invention.
[0079] Extracts according to the second aspect of the invention may
be used to treat, and in particular prevent the development, of
disease states that are characterised by inappropriate platelet
aggregation. The inventors have established that the extracts of
the invention are particularly useful for: [0080] (a) preventing or
reducing the occurrence of a hypercoagulable or prothrombotic
state, such as is often associated with conditions such as diabetes
mellitus, inflammatory bowel disease, hyperlipidaemia [0081] (b)
preventing or reducing the development of atherosclerosis [0082]
(c) preventing the development of coronary disease (e.g. myocardial
infarctions and stroke and in preventing further thrombo-embolic
events in patients who have suffered myocardial infarction, stroke
or unstable angina). [0083] (d) preventing the development of
restenosis following angioplasty and bypass procedures. [0084] (e)
treating coronary disease resulting from thrombo-embolic disorders
such as myocardial infarction in conjunction with thrombolytic
therapy. [0085] (f) preventing or reducing the risk of deep vein
thrombosis [0086] (g) benefiting the circulation to maintain good
circulatory health [0087] (h) maintaining healthy blood flow in the
cardiovascular system.
[0088] It will be appreciated that extracts of the invention will
have general health benefits for maintaining cardiovascular and
heart health by reducing platelet aggregation, benefiting the
circulation, and/or normalizing or otherwise benefitting blood flow
(e.g. as outlined in (g) and (h) above).
[0089] Indeed so advantageous are these uses of the extracts, that
the invention further provides a fruit extract prepared according
to the methods of the invention for use as a medicament for
normalizing or otherwise benefiting blood flow in a patient. The
invention also provides a fruit extract comprising a glycosylated
phenolic acid or a phenolic ester, or derivatives thereof; a
glycosylated flavonoid; and a nucleoside for use as a medicament
for normalizing or otherwise benefiting blood flow in a
patient.
[0090] Compositions comprising extracts of the invention will be
useful as pharmaceutical products but will also represent
beneficial functional foods or "nutraceuticals". Accordingly
preferred uses of the compositions are as medicaments and
functional foods or drinks (as outlined below).
[0091] Preferred fruit extracts of the invention are aqueous
extracts from ripe, (i.e. red) tomatoes, and are water soluble.
[0092] The term "water soluble" as used herein means that the
tomato extracts are soluble at room temperature, e.g. at 25.degree.
C. The extracts have also been found to be water soluble at much
lower temperatures, for example at temperatures as low as 4.degree.
C.
[0093] The extracts contain no, or negligible concentrations of,
lycopene. For example, the extracts contain less than 0.5% by
weight (dry weight) of lycopene, e.g. less than 0.1%, or less than
0.05%, or less than 0.01%, or less than 0.005%, or less than
0.001%, or less than 0.0005%, or less than 0.0001%, by weight (dry
weight) of lycopene.
[0094] The extracts are substantially free from water-insoluble
particulate material. Thus, for example, they contain less than
0.5% by weight (dry weight) of water-insoluble particulate
material, e.g. less than 0.1%, or less than 0.05%, or less than
0.01%, or less than 0.005%, or less than 0.001%, or less than
0.0005%, or less than 0.0001%, by weight (dry weight) of
water-insoluble particulate material. In one embodiment, the
extracts contain no water-insoluble particulate material.
[0095] The term "active fraction" as used herein refers to a
fraction isolated from a tomato extract, which fraction has the
ability to reduce platelet aggregation.
[0096] The inventors research (See Example 1) established that
fruit extracts may be prepared in which a number of bioactives are
enriched or maintained in an extract that is subsequently to be
used to prevent or treat medical conditions characterised by
inappropriate platelet aggregation. The methods of the first aspect
of the invention were developed in order to maintain such
bioactives. The inventors have established that extracts prepared
according to invention comprise a number of bioactive molecules
including:
[0097] (A) Bioactive Phenolic Compounds in the Extract of the
Invention
[0098] The inventors have established that a number of molecules
based on phenol and derivatives thereof are contained within fruit
and have efficacy for preventing platelet aggregation (see Example
1).
[0099] In particular cinnamic acid, and derivatives thereof, were
found to be particularly effective for inhibiting platelet
aggregation. Therefore the methods of the first aspect of the
invention were designed to ensure the extract comprises cinnamic
acid or a derivative thereof as defined by formula I:
##STR00001##
[0100] In formula I, R1 and R2 and R3 may be independently selected
from H, OH and Ome.
[0101] The compound may be Cinnamic acid per se (where R1, R2 and
R3 of formula I are H) or may be any one of a number of
derivatives, including:
[0102] 4-Hydroxycinnamic acid (p-Coumaric acid)
##STR00002##
[0103] 3,4-Dihydroxycinnamic acid (Caffeic acid)
##STR00003##
[0104] 4-Hydroxy-3-methoxycinnamic acid (Ferulic acid)
##STR00004##
[0105] 4-Hydroxy-3,5-dimethoxycinnamic acid (Sinapic acid)
##STR00005##
[0106] The inventors also identified a further class of plant
phenol derivatives, benzoic acids and derivatives thereof, in fruit
extracts that are also effective for inhibiting platelet
aggregation. Therefore, the methods of the first aspect of the
invention may be adjusted to ensure that the extract comprises a
benzoic acid or derivative thereof as define by formula II:
##STR00006##
[0107] In formula II, R1 and R2 and R3 are as previously
defined.
[0108] Accordingly preferred extracts according to the second
aspect of the invention may comprise Benzoic acid per se (wherein
each of R1, R2 and R3 are H) or any one of a number of derivatives,
for example:
[0109] 4-Hydroxybenzoic acid (p-Hydroxybenzoic acid)
##STR00007##
[0110] 3,4-Dihydroxybenzoic acid (Protocatechuic acid),
##STR00008##
[0111] 3,4,5-Trihydroxybenzoic acid (Gallic Acid)
##STR00009##
[0112] 4-Hydroxy-3,-methoxybenzoic acid (Vanillic acid)
##STR00010##
[0113] 4-Hydroxy-3,5-dimethoxybenzoic acid (syringic acid)
##STR00011##
[0114] During the inventors work with fruit extracts they were
surprised to discover that phenolic bioactives that are conjugated
with other molecules either via an ester linkage at the carboxylic
acid group, to form a carboxylic ester, or via an ether linkage at
a phenolic hydroxyl substituent, to form a glycoside, were
particularly efficacious for reducing platelet aggregation and
therefore useful for treating or preventing the development of a
variety of cardiovascular conditions. Therefore, the method of the
first aspect of the invention was designed to ensure that the
extract comprised a phenolic bioactive conjugated with other
molecules.
[0115] It is preferred that the bioactives are conjugated to sugars
to form glycosides. The inventors have found that a number of
different bioactive glycosides are contained within the extracts.
Accordingly, by the term "glycoside", we mean at least one hexose
or pentose sugar residue conjugated to the bioactive; preferably
1-5 and more preferably 1-3 monosaccharide units are added by
reaction at an OH group on the bioactive compound. Glucose,
galactose or arabinose and also di-/tri-saccharides of these sugars
are most preferably added to the compound to form phenolic acid
derivative glycosides.
[0116] Alternatively the bioactive compounds may be conjugated to a
number of compounds found in plants (e.g. tartaric acid, quinic
acid) to form esters. Such compounds may be open chain compounds
such as tartaric acid, or heterocyclic compounds such as quinic
acid and may be derived from the carbohydrate pathway in plants.
Tartaric acid or quinic acid are most preferably added to the
compound to form phenolic ester derivatives.
[0117] It is preferred that method of the invention enriches the
extract such that it comprises a glycoside selected from the group
comprising: Caffeic acid 3-O-glycoside, Caffeic acid 4-O-glycoside,
Ferulic acid 4-O-glycoside, p-Coumaric acid 4-O-glycoside, or an
esterified derivative selected from the group comprising
Caffeoylquinic acids (e.g. 3-O-Caffeoylquinic acid,
4-O-Caffeoylquinic acid or 5-O-Caffeoylquinic acid), Feruloylquinic
acids, p-Coumaroylquinic acids, Caffeoyltartaric acids,
Feruloyltartaric acids, p-Coumaroyltartaric acids, dimers of quinic
acid derivatives.
[0118] Accordingly the extract of the second aspect of the
invention may comprise at least one glycoside of Cinnamic acid or
derivative thereof selected from the compounds listed above and may
also comprise at least one glycoside of a Benzoic acid or
derivative thereof selected from the compounds listed above.
[0119] (B) Bioactive Flavonoid Compounds in the Extract of the
Invention
[0120] The inventors also established that optimal inhibition of
platelet aggregation is achieved in extracts that also contain a
flavonoid, or derivatives thereof.
[0121] The extract preferably contains a flavonoid of general
formula (III):
##STR00012##
wherein R5, R6 and R7 are independently H, OH.
[0122] Preferably the extract comprises one of the following
flavonoids:
##STR00013##
[0123] It is most preferred that the extract contains Quercetin or
Kaempferol or derivatives thereof.
[0124] The inventors have also established that bioactive
flavonoids that are conjugated with other molecules are
particularly efficacious for reducing platelet aggregation.
Therefore, in a most preferred embodiment of the invention, the
extract comprises flavonoid compounds conjugated as defined above
(i.e. to sugars, tartaric acid, quinic acid and the like).
[0125] Naringenin and derivatives thereof represent another type of
flavonoid found in extracts according to the second aspect of the
invention which the inventors have found have activity for
inhibiting platelet aggregation. Therefore the extract may comprise
molecules of general formula IV.
##STR00014##
[0126] R4, R8 and R9 are as previously defined.
[0127] A preferred compound defined by Formula IV, contained within
the extract, is Naringenin.
##STR00015##
[0128] The inventors have also established that the compounds of
General formula (IV) that are conjugated with other molecules are
particularly efficacious for reducing platelet aggregation.
Therefore, in a most preferred embodiment of the invention, the
extract comprises flavonoid compounds conjugated as defined above
(i.e. to sugars, tartaric acid, quinic acid and the like
[0129] A most preferred glycoslyated flavonoid compound found in
the extracts of the invention is Naringin.
##STR00016##
[0130] The inventors have found that preferred extracts may
comprise phenolic and flavonoid bioactive compounds discussed above
that are conjugated with each other. For example, Caffeic acid
4-O-Rutinoside is a molecule with anti-platelet aggregation
properties where a glycoside link is made between Caffeic acid and
a sugar residue on Rutin (which comprise Quercetin).
[0131] (C) Nucleosides/Nucleotides
[0132] As contemplated in WO 99/55350, fruit extracts with
anti-platelet activity may further comprise a nucleoside. The
extract may comprise at least one nucleoside selected from
Adenosine 5'-monophosphate, Cytidine, Uridine, Adenosine, Inosine,
Guanosine and Guanosine 5'-monophosphate.
[0133] It will be appreciated that the inventors have identified a
number of bioactive compounds in different fractions of tomato
extracts. They were then able to adapt methods for preparing fruit
abstracts such that the active compounds they identified were
maintained and/or enriched in such fruit extracts.
[0134] According to a third aspect of the invention there is
provide a fruit extract comprising: [0135] (a) glycosylated
phenolic acid or a phenolic ester, or derivatives thereof; [0136]
(b) a glycosylated flavonoid; and [0137] (c) a nucleoside.
[0138] (a) The glycosylated phenolic acid is preferably a
glycosylated cinnamic acid or derivative thereof. The extract most
preferably comprises at least one of Caffeoyl-4-O-quinic acid,
Caffeoyl-4-O-glucoside, Coumaroyl-4-O-glycoside (gluc/gal) or
Coumaroyl-4-O-glycoside (disaccharide). The extract may comprise 1,
2, 3 or each of these glycosides. In a preferred embodiment of the
invention, the fruit extract according to the third aspect of the
invention comprises a glycosylated cinnamic acid or derivative
thereof and a benzoic acid or derivate thereof as discussed
above.
[0139] It is most preferred that the extract comprise Caffeic acid
glucoside; and/or p-Coumaric acid hexose/dihydrokaempferol hexose;
and/or Ferulic acid glycoside; and/or a p-Coumaric acid
derivative
[0140] (b) The glycosylated flavonoid is preferably Naringin,
Quercetin-3-O-glucoside or Rutin. The extract may comprise one, two
or each of these glycosides. The bioactive is most preferably
Rutin.
[0141] (c) The nucleoside may be any one of AMP, Uridine,
Adenosine, Guanosine or GMP. The extract may comprise 1, 2, 3, 4 or
each of these nucleosides. The nucleoside is preferably Guanosine
and/or Adenosine 3'-mono phosphate
[0142] The fruit extract according to the third aspect of the
invention may also optionally contain a steroidal glycoside such as
Tomatidine.
[0143] The fruit extracts preferably contains no fats or
carotenoids.
[0144] Two preferred extracts, which may be prepared from fruits
and particularly tomato according to the methods of the invention,
were found to comprise the following bioactive compounds in the
specified concentrations (mg/g):
[0145] (1) A preferred extract, prepared according to the methods
described in Example 2, comprises:
[0146] (a) The following Glycosylated phenolic acid or phenolic
esters:
[0147] Caffeic acid glucoside (0.01-1 mg/g);
[0148] p-Coumaric acid hexose/dihydrokaempferol hexose mixture
(0.05-2.5 mg/g)
[0149] Ferulic acid glycoside (0.025-5 mg/g); and
[0150] p-Coumaric acid derivative (0.01-1 mg/g).
[0151] (b) The glycosylated flavonoid: Rutin (0.01-1 mg/g).
[0152] (c) The following nucleosides/nucleotides:
[0153] Guanosine (0.1-5 mg/ml); and
[0154] Adenosine 3'-monophosphate (0.5-25 mg/ml)
[0155] (2) A preferred low sugar extract, prepared according to the
methods described in Example 3, comprises:
[0156] (a) The following Glycosylated phenolic acid or phenolic
esters:
[0157] Caffeic acid glucoside (1-25 mg/g);
[0158] p-Coumaric acid hexose/dihydrokaempferol hexose mixture
(5-100 mg/g);
[0159] Ferulic acid glycoside (25-300 mg/g); and
[0160] p-Coumaric acid derivative (1-25 mg/g)
[0161] (b) the glycosylated flavonoid: Rutin (1-25 mg/g)
[0162] (c) the following nucleosides/nucleotides:
[0163] Guanosine (1-50 mg/g); and
[0164] Adenosine 3'-mono phosphate (1-50 mg/g);
[0165] Two specific tomato extracts embodying the second or third
aspects of the invention are identified in table 1. Table 1
identifies 16 compounds (in column 3 and ID No. is also provided in
column 2) that were isolated and assayed (see Example 1) and found
to have most anti-platelet activity. Accordingly it is preferred
that extracts according to the second or third aspects of the
invention comprise each of these 16 bioactive compounds. It will be
appreciated that the methods of the first aspect of the invention
are preferably designed to optimise the activity of these compounds
in a fruit extract.
[0166] Table 1 also identifies the ranges (mg/g wet weight) of each
bioactive compound found in extracts prepared according to the
methods specified in Examples 2 and 3 respectively. The average
concentration (mg/g) is also shown. Most preferred extracts
according to the second or third aspects of the invention comprise
bioactive compounds in these specified ranges.
TABLE-US-00001 TABLE 1 antiplatelet compounds in tomato extract,
grouped by compound type. Preferred Extract Preferred Low Sugar
prepared according to Extract prepared according methods of Example
2 to methods of Example 3 lower upper lower upper Type of Compound
Bioactive range range average range range average bioactive ID
Compound mg/g mg/g mg/g mg/g mg/g mg/g Nucleotides 2 Adenosine
0.382 2.440 2.033 1.800 2.927 2.439 4 Guanosine 0.400 1.759 1.466
6.970 19.354 16.128 5 Adenosine 3'- 1.312 11.491 9.576 6.421 16.087
13.406 monophospate 6 Adenosine 5'- monophospate Phenolic 8
p-Coumaric acid 0.050 0.456 0.380 9.418 11.867 9.889 glycosides
hexose/quinic acid derivative 9 Caffeic acid 0.069 0.477 0.398
3.736 13.402 11.168 glucoside 10 Ferulic acid 0.028 0.048 0.040
0.706 1.340 1.117 hexose 11 p-Coumaric acid 0.277 0.997 0.831
26.121 40.288 33.573 hexose/ dihydrokaempferol hexose mixture 12
p-Coumaric acid/ 0.170 1.419 1.182 90.872 131.722 109.768 caffeic
acid conjugate, glycosylated 13 Ferulic acid 0.155 1.199 0.999
85.333 199.679 166.399 glycoside 14 Chlorogenic acid 0.131 0.953
0.794 18.274 43.366 36.138 Phenolic ester 15 p-Coumaric 0.105 0.332
0.277 8.620 16.584 13.820 derivatives acid derivative Flavonoid 23
Quercetin-3-O- 0.050 0.324 0.270 8.463 13.257 11.048 glycosides
glycoside 25 Quercetin-3-O- 0.157 0.610 0.508 14.679 24.799 20.666
trisaccharides 26 Naringin 0.739 2.103 1.753 38.016 61.709 51.424
27 Rutin 0.583 2.804 2.337 50.688 106.147 88.456
[0167] Following detailed analysis of bioactive compounds contained
within a tomato extract the inventors came to the conclusion that a
further 16 compounds also had anti-aggregation activity. It was
therefore realised that most preferred extracts according the
second or third aspects of the invention contain the 32 bioactive
compounds identified in Table 2.
TABLE-US-00002 TABLE 2 Most preferred extracts comprising 32
bioactive compounds Preferred Extract Preferred Low Sugar prepared
according to Extract prepared according methods of Example 2 to
methods of Example 3 lower upper lower upper Compound Bioactive
range range average range range average Group ID Compound mg/g mg/g
mg/g mg/g mg/g mg/g Nucleosides 1 Cytidine 0.487 2.051 1.709 21.971
36.911 30.759 2 Adenosine 0.382 2.440 2.033 1.800 2.927 2.439 3
Uridine 0.414 2.089 1.741 21.917 31.340 26.117 4 Guanosine 0.400
1.759 1.466 6.970 19.354 16.128 Nucleotides 5 Adenosine 3'- 1.312
11.491 9.576 6.421 16.087 13.406 monophospate 6 Adenosine 5'-
monophospate Phenolic acid 7 Mixed phenolic 0.352 0.956 0.796
20.982 145.537 121.281 glycosides acid glycosides 8 p-Coumaric acid
0.050 0.456 0.380 9.418 11.867 9.889 hexose/quinic acid derivative
9 Caffeic acid 0.069 0.477 0.398 3.736 13.402 11.168 glucoside 10
Ferulic acid 0.028 0.048 0.040 0.706 1.340 1.117 hexose 11
p-Coumaric acid 0.277 0.997 0.831 26.121 40.288 33.573 hexose/
dihydrokaempferol hexose mixture 12 p-Coumaric acid/ 0.170 1.419
1.182 90.872 131.722 109.768 caffeic acid conjugate, glycosylated
13 Ferulic acid 0.155 1.199 0.999 85.333 199.679 166.399 glycoside
14 Chlorogenic acid 0.131 0.953 0.794 18.274 43.366 36.138 Phenolic
ester 15 p-Coumaric acid 0.105 0.332 0.277 8.620 16.584 13.820
derivatives derivative 16 Caffeoyl-quinic 0.066 0.701 0.584 13.850
85.176 70.980 acid dimer #1 17 Caffeoyl-quinic 0.142 0.701 0.584
12.672 22.731 18.943 acid dimer #2 Phenolic acids 18 Caffeic acid
0.058 0.873 0.727 5.842 9.042 7.535 19 p-coumaric acid 0.046 0.488
0.407 11.403 27.568 22.974 20 Benzoic acid 0.006 0.077 0.064 0.959
1.554 1.295 21 Ferulic acid 0.016 0.140 0.117 0.584 1.113 0.927 22
Cinnamic acid 0.028 0.084 0.070 1.966 6.896 5.747 Flavonoid 23
Quercetin-3-O- 0.050 0.324 0.270 8.463 13.257 11.048 glycosides
glycoside 24 Kaempferol 0.008 0.049 0.041 1.269 5.277 4.398
glycoside 25 Quercetin-3-O- 0.157 0.610 0.508 14.679 24.799 20.666
trisaccharides 26 Naringin 0.739 2.103 1.753 38.016 61.709 51.424
27 Rutin 0.583 2.804 2.337 50.688 106.147 88.456 Flavonoid ester 28
Flavonoid 0.004 0.032 0.027 0.846 1.733 1.444 derivatives conjugate
29 Trace 1.253 3.900 3.250 90.660 319.469 266.224 flavonoids +
glycosides Flavonoids 30 Quercetin 0.014 0.130 0.108 3.787 20.578
17.149 31 Kaempferol 0.039 0.180 0.150 3.749 8.230 6.858 32
Naringenin trace 1.540 trace trace 25.600 trace
[0168] A preferred extract according to the third aspect of the
invention comprises the recombination of fraction 1, fraction 2 and
fraction 3 as referred to in Example 1 (1.1.3) to from a recombined
extract. The inventors have found that such a recombined extract is
enriched in the bioactives discussed above and had a surprisingly
improved efficacy for inhibiting platelet aggregation.
[0169] Pharmaceutical and Nutraceutical Formulations Comprising the
Fruit Extract
[0170] The fruit extracts of the invention may be formulated for
oral administration. As such, they can be formulated as solutions,
suspensions, syrups, tablets, capsules, lozenges and snack bars,
inserts and patches by way of example. Such formulations can be
prepared in accordance with methods well known to the art.
[0171] For example, the extract may be formed into a syrup or other
solution for administration orally, for example as a health drink.
One or more excipients selected from sugars, vitamins, flavouring
agents, colouring agents, preservatives and thickeners may be
included in such syrups or solutions. Tonicity adjusting agents
such as sodium chloride, or sugars, can be added to provide a
solution of a particular osmotic strength, for example an isotonic
solution. One or more pH-adjusting agents, such as buffering agents
can also be used to adjust the pH to a particular value, and
preferably maintain it at that value. Examples of buffering agents
include sodium citrate/citric acid buffers and phosphate
buffers.
[0172] Alternatively, the extract may be dried (e.g. by spray
drying or freeze drying) and the dried product formulated in a
solid or semi solid dosage form, for example as a tablet, lozenge,
capsule, powder, granulate or gel.
[0173] Compositions containing the extracts can be prepared without
any additional components. Alternatively, they may be prepared by
adsorbing on to a solid support; for example a sugar such as
sucrose, lactose, glucose, fructose, mannose or a sugar alcohol
such as xylitol, sorbitol or mannitol; or a cellulose derivative.
Other particularly useful adsorbents include starch-based
adsorbents such as cereal flours for example wheat flour and corn
flour.
[0174] For tablet formation, the extract may typically be mixed
with a diluent such as a sugar, e.g. sucrose and lactose, and sugar
alcohols such as xylitol, sorbitol and mannitol; or modified
cellulose or cellulose derivative such as powdered cellulose or
microcrystalline cellulose or carboxymethyl cellulose. The tablets
will also typically contain one or more excipients selected from
granulating agents, binders, lubricants and disintegrating agents.
Examples of disintegrants include starch and starch derivatives,
and other swellable polymers, for example crosslinked polymeric
disintegrants such as cross-linked carboxymethylcellulose,
crosslinked polyvinylpyrrolidone and starch glycolates. Examples of
lubricants include stearates such as magnesium stearate and stearic
acid. Examples of binders and granulating agents include
polyvinylpyrrolidone. Where the diluent is not naturally very
sweet, a sweetener can be added, for example ammonium
glycyrrhizinate or an artificial sweetener such as aspartame, or
sodium saccharinate.
[0175] The extracts can also be formulated as powders, granules or
semisolids for incorporation into capsules. When used in the form
of powders, the extracts can be formulated together with any one or
more of the excipients defined above in relation to tablets, or can
be presented in an undiluted form. For presentation in the form of
a semisolid, the dried extracts can be dissolved or suspended in a
viscous liquid or semisolid vehicle such as a polyethylene glycol,
or a liquid carrier such as a glycol, e.g. propylene glycol, or
glycerol or a vegetable or fish oil, for example an oil selected
from olive oil, sunflower oil, safflower oil, evening primrose oil,
soya oil, cod liver oil, herring oil, etc. Such extracts can be
filled into capsules of either the hard gelatine or soft gelatine
type or made from hard or soft gelatine equivalents, soft gelatine
or gelatine-equivalent capsules being preferred for viscous liquid
or semisolid fillings.
[0176] Extracts according to the invention can also be provided in
a powder form for incorporation in to snack food bars for example
fruit bars, nut bars, and cereal bars. For presentation in the form
of snack food bars, the extracts can be admixed with any one or
more ingredients selected from dried fruits such as sun-dried
tomatoes, raisins and sultanas, groundnuts or cereals such as oats
and wheat.
[0177] Extracts according to the invention may also be provided in
a powder form for reconstitution as a solution. As such they can
also contain soluble excipients such as sugars, buffering agents
such as citrate and phosphate buffers, and effervescent agents
formed from carbonates, e.g. bicarbonates such as sodium or
ammonium bicarbonate, and a solid acid, for example citric acid or
an acid citrate salt.
[0178] In one preferred embodiment, an extract according to the
invention is provided in powder form optionally together with a
preferred solid (e.g. powdered) excipient for incorporation into
capsules, for example a hard gelatine capsule.
[0179] A solid or semisolid dosage form of the present invention
can contain up to about 1000 mg of the composition, for example up
to about 800 mg.
[0180] The extract can be presented as food supplements or food
additives, or can be incorporated into foods, for example
functional foods or nutraceuticals.
[0181] The extracts of the invention can be presented in the form
of unit dosage forms containing a defined concentration of
compounds with activity for inhibiting platelet aggregation. Such
unit dosage forms can be selected so as to achieve a desired level
of biological activity. For example, a unit dosage form can contain
an amount of up to 1000 mg (dry weight) of a composition according
to the present invention, more typically up to 800 mg, for example
50 mg to 800 mg, e.g. 100 mg to 500 mg. Particular amounts of the
composition that may be included in a unit dosage form may be
selected from 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350
mg, 400 mg, 450 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg and 800
mg.
[0182] The extracts of the invention can be included in a
container, pack or dispenser together with instructions for
administration.
[0183] Preferred products comprising extracts according to the
invention are defined in Example 5.
[0184] Dosing
[0185] For the treatment of the diseases and conditions concerned,
the quantity of the extract according to the invention administered
to a patient per day will depend upon the particular condition or
disease under treatment and its severity, and ultimately it will be
at the discretion of the physician. The amount administered however
will typically be a non-toxic amount effective to treat the
condition in question.
[0186] For a composition which contains sugars, the recommended
daily dose of a fruit extract prepared according to the methods of
the invention is between 0.5 g and 20 g and more preferably between
2 g and 7 g. A daily dose may be about 3 g. For a low-sugar
composition (see above), the recommended daily dose may be between
10 mg and 500 mg and is more preferably between about 85 mg and
about 150 mg.
[0187] A typical daily dosage regime for a human patient suffering
from a cardiovascular disease may be from about 70 mg to 285 mg,
preferably about 25 mg to 100 mg per kilogram body weight of an
extract containing fruit sugars and may be from about 1 mg to 2.25
mg100 mg per kilogram body weight of a low-sugar extract.
[0188] The extract can be administered in single or multiple dosage
units per day, for example from one to four times daily, preferably
one or two times daily. It is most preferred that the extract is
given as a single daily dose.
[0189] The extracts can be administered in the form of tomato juice
or concentrates thereof alone or in admixture with other fruit
juices such as orange juice.
[0190] Indications of Therapeutic Effectiveness
[0191] The ability of compositions comprising extracts of the
invention to provide beneficial therapeutic effects may be assessed
with reference to a number of different parameters. The Examples
below provide details of suitable protocols for the assessment of
platelet aggregation or primary haemostasis, either of which may be
investigated in order to evaluate therapeutic effectiveness. The
PFA-100.RTM. platelet function analyzer described in the Examples
is a relatively new device for the assessment of primary
haemostasis, but has been well validated (see, for instance, "The
platelet-function analyzer (PFA-100.RTM.) for evaluating primary
hemostasis" by M. Franchini Hematology, Volume 10, Issue 3 June
2005, pages 177-181).
[0192] Other parameters that may be assessed for this purpose
include blood fluidity and blood flow, where an increase in
fluidity or flow will generally be indicative of a therapeutically
useful effect.
[0193] Methods of Measuring Blood Fluidity
[0194] A direct measurement of blood fluidity can be obtained using
a Micro Channel Array Flow Analyser (MC-FAN), such as the MC-FAN
HR300 available from Arkray, which mimics capillary vessels.
[0195] A suitable protocol for use of a MC-FAN is provide in
"Determinants of the daily rhythm of blood fluidity", by Tatsushi
Kimura, Tsutomu Inamizu, Kiyokazu Sekikawa, Masayuki Kakehashi and
Kiyoshi Onari (Journal of Circadian Rhythms 2009, 7:7).
[0196] Briefly microgrooves with width 7 .mu.m, length 30 .mu.m,
depth 4.5 1-1 m are formed, for example by photo-fabrication on the
surface of a single crystal silicon chip. Suitable chip dimensions
may be around 15.times.15 mm. The microgrooves are then formed into
leak-proof microchannels that represent capillaries. This
conversion into channels may, for instance, be achieved by tightly
covering the channels with a cover such as an optically flat glass
plate. Suitable grooves may be transformed into hermetic
microchannel by soldering of an optically polished glass plate.
[0197] The dimensions of the microchannels are such that the volume
of fluid which flows through one flow path is extremely small.
Accordingly, it is desirable to replicate the flow channels in
order to facilitate measurement of the flow rate. The reference
cited above describes the production of a device in which 8736 flow
paths of the same size are created. The silicon substrate may then
be mounted onto the microchannel flow system, MC-FAN (Hitachi
Haramachi Electronics Co., Ltd, Ibaragi, Japan), which makes it
possible to directly observe the flow of blood cell elements
through the microchannel under a microscope connected to an image
display unit. Flow can be continuously viewed while the passage
time for a given volume of blood is determined automatically.
[0198] A suitable value of blood passage may be expressed as a
function of the actual whole blood passage time over saline
solution passage time of 12 seconds at a pressure of 20 em H20, as
follows:
Blood .times. .times. passage .times. .times. time .times. .times.
( revised .times. .times. value ; sec ) = Whole .times. .times.
blood .times. .times. passage .times. .times. time .times. .times.
( actual .times. .times. value ) Saline .times. .times. solution
.times. .times. passage .times. .times. time .times. 12
##EQU00001##
[0199] Methods of Measuring Blood Flow
[0200] Doppler ultrasound flowmetry is a widely used method for
assessment of blood flow through intact blood vessels in vivo.
Suitable methods using Doppler ultrasound are well known to those
skilled in the art, and include those described in "Measurement of
blood flow by ultrasound: accuracy and sources of error." By R. W.
Gill (Ultrasound Med Bioi. 1985 Jui-August, 11(4):625-41).
BRIEF DESCRIPTION OF THE DRAWINGS
[0201] The invention will now be illustrated, but not limited, by
the following examples, and with reference to the accompanying
drawings, in which:
[0202] FIG. 1A-1F: represents examples of dose-response curves of %
inhibition of aggregation versus inhibitor solution concentration
generated for (1A) Compound 1; (1B) Compound 5; (1C) Compound 9;
(1D) Compound 18; (1E) Compound 23; and (1F) Compound 30 as
discussed in Example 1. (1A) and (1B) represent dose-response
curves of % inhibition of ADP-mediated aggregation. (1C) and (1D)
represent dose response curves of % inhibition of collagen-mediated
aggregation. (1E) and (1F) represent dose-response curves of %
inhibition of arachidonic acid-mediated aggregation.
[0203] FIG. 2: defines a preferred method according to the first
aspect of the invention for making fruit extracts as discussed in
Example 2.
[0204] FIG. 3: is an HPLC chromatogram of syrup produced using the
method detailed in Example 2. Bioactive compounds are numbered on
the chromatogram.
[0205] FIG. 4A-4B: defines a preferred method according to the
first aspect of the invention for making low sugar fruit extracts
as discussed in Example 3. 4A shows steps 1-4; 4B shows steps
5-7.
[0206] FIG. 5: is an HPLC chromatogram of syrup produced using the
method detailed in Example 3. Bioactive compounds are numbered on
the chromatogram.
[0207] FIG. 6: % Change from baseline aggregation in response to
different platelet agonists, 3 hours after consumption of tomato
extract (TE) or control (C) supplements, as described in Example 4.
The platelet agonists used were adenosine diphosphate (ADP) 7.5
.mu.mol/L and 3 .mu.mol/L, and collagen 5 mg/L and 3 mg/L.
Significant differences between TE and C supplements are indicated
on the graph (P<0.001). N=9 for all measurements.
[0208] FIG. 7: Shows average closure times recorded at baseline
(0), t=3 hours (3) after supplementation with TE or C and t=5 hours
(5) after supplementation with TE or C, as described in Example 6.
n=3 for each group. Significant differences between C and TE are
indicated on the graph by* (P=0.011).
EXAMPLE 1
[0209] The present invention is based upon further research that
was conducted in view of the antiplatelet activity identified in
the fruit extract described in WO 99/55350.
[0210] The inventors conducted exhaustive experiments whereby they
further fractionated tomato extracts to identify compounds within
such extracts that were linked to its inhibitory effects on
platelet aggregation. The inventors identified many, many compounds
(not all chemically identified; and not all data presented here)
with the fruit extract that had no or negligible effects on
platelet aggregation. However the inventors were surprised to find
that 32 compounds with notable activity feel into the classes of
chemicals defined by the third aspect of the invention. This
discovery led them to develop the methods of the first aspect of
the invention in order that the activity of such compounds could be
maintained/enriched in fruit extracts.
[0211] 1.1. Methods
[0212] 1.1.1 Preparation of a Tomato Extract as Defined by WO
99/55350.
[0213] A tomato extract was prepared using commercially available
cold-break tomato paste of 28-30.degree. Brix (i.e. 28-30% solids,
w/w) having a browning index (absorbance of a solution of
concentration 12.5 g soluble solids/L at 420 nm) <0.350 AU as
the starting material. The paste was diluted (1:5) with ultrapure
water and large particulate matter was removed by centrifugal
filtration followed by clarification using a Westfalia MSB-14
Separator (a centrifugal disk clarifier) at room temperature.
Smaller particulate matter was then removed by microfiltration at a
temperature not exceeding 45.degree. C., to give a clear
straw-coloured solution containing no insoluble spin-down solids
and capable of passing through a 0.2.mu. filter without loss of
soluble solids. This solution was concentrated by evaporation to a
syrup of 65.degree. Brix, using carefully controlled conditions and
a temperature not exceeding 50.degree. C. to limit the progress of
non-enzymic browning reactions. A flash pasteurisation step
(T=105.degree. C. for 3 seconds) was incorporated at the outset of
the evaporation procedure. The final product was characterised by a
browning index <0.600 AU, and a microbial total plate count of
<1000.
[0214] 1.1.2 Enrichment of the Tomato Extract with the Active
Compounds of Interest and Removal of Inactive Materials
[0215] In order to yield a starting material more concentrated in
bioactive components, sugars were removed from the product
described above as follows.
[0216] A 130 L resin column containing FPX66 resin (Rohm and Haas)
was prepared and equilibrated in ultrapure water at 4.degree. C.
The material described in 1.1.1 was diluted to approximately 8 Brix
with ultrapure water, and passed through the resin column at a flow
rate of approximately 260 L/minute, maintaining the temperature at
4.degree. C. The column permeate was discarded. Once all the
required material had been passed through the column, a water wash
of approximately 130 L was passed through and discarded.
Thereafter, the compounds which had been retained by the resin were
eluted, by passing 130 L of hot water (75.degree. C.) through the
columns, followed by 130 L of 80% ethanol, followed by a further
130 L of hot water. All eluted material was retained and combined
to give approximately 400 L of approximately 25% ethanolic solution
containing the compounds of interest.
[0217] The dilute solution containing the compounds of interest was
concentrated by reverse osmosis using Trisep ACM5 membranes at
temperatures around 30.degree. C. The ethanol/water solvent passed
through this membrane, while all compounds dissolved therein
remained within the membrane. Once the dilute solution had been
concentrated 10-fold, i.e. volume was reduced to 40-50 L,
diafiltration commenced, during which ultrapure water was added to
the retentate at an equal rate to the permeate removal rate. In
this way, the ethanol concentration of the solution was gradually
reduced from 25% to <5%.
[0218] The ethanolic solution at .about.15-20% solids was then
spray-dried using an Anhydro spray-drier to form a fine, golden
powder of <6% moisture content. This was the final enriched
tomato extract, which was used to isolate antiplatelet components
of interest.
[0219] 1.1.3 Isolation and Characterisation of Individual Bioactive
Compounds in the Tomato Extract
[0220] A stock solution of 50 mg/mL was prepared from the dry
powder described in 1.1.2, by dissolving it in ultra-pure
HPLC-grade water. Semi-preparative HPLC was carried out using a
Luna C18(2) 5.mu. semi-preparative column, 100.times.4.6 mm,
injecting 1004 onto the column at a time. Using a fraction
collector, the UV-absorbing components contained in the tomato
extract were divided into three bulk fractions. Fraction 1
contained largely nucleosides and nucleotides. Fraction 2 contained
largely phenolic acid glycosides/esters, and phenolic acids.
Fraction 3 contained largely flavonoid glycosides and flavonoids.
The three bulk fractions were dried by freeze-drying, and
redissolved in water to give solutions of 50 mg/mL. Each fraction
in turn was then subjected to further semi-preparative HPLC using
the same column but with different gradients, adapted to the
polarity and elution characteristics of each fraction. From each
bulk fraction, up to 10 individual or mixed fractions were
collected using a fraction collector.
[0221] The individual fractions were freeze-dried and redissolved
in 1 mL pure water. Each fraction was then examined by analytical
HPLC-MS, using a Luna C18(2) 382 analytical column, 100.times.4.6
mm, running an acetonitrile/formic acid gradient. Characteristics
of each isolated fraction were determined by collection of its UV
spectrum via a diode-array detector, and by examination of its
characteristic ions generated by electrospray MS in positive ion
mode.
[0222] Where necessary, final purifications (e.g. to remove minor
contaminants) were carried out by further HPLC. Finally purified
compounds were freeze-dried and stored frozen. Stock solutions were
prepared at 50 mg/mL and diluted into HPLC buffer to produce 6
concentration levels, which were used to calibrate the HPLC method,
so that response factors could be calculated for each individual
compound. These calibration curves and response factors were then
used to quantify the compounds present in the tomato extract. The
structural types/identities of the bioactive compounds isolated are
shown in Table 3.
[0223] 1.1.4 Methods of Assaying Activity for Inhibiting Platelet
Aggregation
[0224] The experimental protocol described below was devised to
determine the IC50 values of compounds isolated as described in
1.1.3. Crude bioassays to evaluate inhibition of platelet
aggregation in vitro were performed on some crude extracts (data
not shown) to help select fine fractions/compounds identified by
HPLC for functional activity. This approach was considered
necessary to avoid the need to assay each and ever compound (the
would be thousands) in the fruit extracts.
[0225] An IC50 value represents the amount of a compound, in mg,
required to inhibit by 50% the platelet aggregation induced under
standardised conditions in 1 mL platelet-rich plasma, in comparison
with control samples.
[0226] The activity of the 32 most active compounds is given in
Table 4.
[0227] Phlebotomy and Blood Samples
[0228] Blood for in vitro studies was collected from drug-free,
healthy human volunteers, both male and female, aged 18-60 years,
with normal platelet function. Subjects declared that they had not
consumed drugs or supplements known to affect platelet function for
a minimum of 10 days before providing a blood sample. Blood was
collected after single venepuncture to an antecubital vein through
siliconized needles into plastic citrated blood collection tubes
(Sarstedt Monovettes, final concentration sodium citrate, 13
mmol/L). All blood was maintained at 37.degree. C. from the time of
blood sampling.
[0229] Preparation of Platelet-Rich Plasma
[0230] Platelet-rich plasma (PRP) was obtained by centrifugation of
citrated blood for 15 minutes at 200.times.g, and was adjusted with
platelet-poor plasma to a standard platelet number of
320.+-.20.times.10.sup.9 /L prior to use. PRP was used for platelet
function measurements within two hours.
[0231] Platelet Agonists
[0232] The following agonists were used for platelet function
measurements. Adenosine diphosphate (ADP), final concentration 10
.mu.mol/L; collagen, final concentration 5 mg/L; arachidonic acid,
final concentration 500 U/L (all from Helena Biosciences,
Sunderland, UK); thrombin receptor-activating peptide (TRAP), final
concentration 25 nmol/L (Sigma-Aldrich, Poole, UK). Agonists were
prepared from stock solutions immediately before use, diluting into
warmed physiological saline (0.9% NaCl).
[0233] Preparation of Platelet Inhibitor Solutions Individual
platelet inhibitors were prepared at a concentration of between 500
g/L and 100 g/L in either physiological saline, ultra-pure methanol
or ultra-pure DMSO (Sigma-Aldrich, Poole, UK) and stored frozen
until required. Stock solutions were then diluted with
physiological saline immediately prior to use.
[0234] Incubation of Platelet Inhibitors with PRP
[0235] 450 .mu.L PRP was incubated with 50 .mu.L diluted inhibitor
solution at 37.degree. C. for 10 minutes, in low-retention
epindorrfs. Inhibitor solutions were diluted such that the final
concentration of methanol or DMSO in the PRP sample never exceeded
2%. Suitable control samples, containing 50 .mu.L physiological
saline matched for methanol or DMSO content as appropriate, were
incubated simultaneously. For each inhibitor compound, 5 incubation
concentrations were used; final concentrations of 0.05 mg/mL, 0.10
mg/mL, 1.00 mg/mL, 5.00 mg/mL and 10 mg/mL were used as
standard.
[0236] Measurement of Platelet Aggregation and Inhibition of
Aggregation
[0237] After incubation with platelet inhibitors, PRP samples were
transferred to glass cuvettes and the extent of aggregation induced
by either ADP, collagen, TRAP or arachidonic acid was monitored
over 10 minutes on a platelet aggregometer (PACKS 4, Helena
Biosciences, Sunderland, UK). A control sample was run with each
sample set. From the aggregation curves generated, the area under
the curve was calculated for each PRP sample, and the inhibition of
aggregation achieved at each inhibitor concentration was calculated
by comparing the area under the curve for these PRP samples with
that of the control sample. The inhibition of aggregation was
expressed as % inhibition, compared to control, and from the 6 data
points obtained per inhibitor compound, a dose-response curve was
constructed. This curve was then used to predict the IC50 value for
that inhibitor compound, as shown in 1.2, Results, and FIG. 1.
[0238] For each blood sample obtained, 6-point dose-response curves
for 2 different inhibitory compounds could be generated. These
experiments were repeated such that for each inhibitory compound,
at least 3 (most often 7-10) different IC50 values were obtained on
different days, using blood from different subjects (this applies
to each agonist of interest). An average of the different IC50s was
then taken and these values are quoted in 1.2, Results, Table
4.
[0239] 1.2 Results
[0240] The physiochemical properties of the 32 compounds found to
have most antiplatelet activity (see below) are summarised in Table
3.
TABLE-US-00003 TABLE 3 Physiochemical Properties of Bioactive
Compounds identified in Fruit Extracts Compound Mass/characteristic
Group ID Bioactive Compound RT (s) .lamda. max ions (POS mode)
Nucleosides 1 Cytidine 1.24 275 487, 244 2 Adenosine 3.17 260 268,
136 3 Uridine 2.59 270 267, 113 4 Guanosine 3.9 260 (278sh) 284,
152 Nucleotides 5 Adenosine 3'- 1.6 260 348, 136 monophospate 6
Adenosine 5'- 1.78 260 348, 136 monophospate Phenolic acid 7 Mixed
phenolic 8.0-9.0 Mixture glycosides acid glycosides 8 p-Coumaric
acid 9.02 300 469, 147, 119 hexose/quinic acid derivative 9 Caffeic
acid 9.39 290 319, 163 glucoside 10 Ferulic acid 9.67 295, 315 265,
177 hexose 11 p-Coumaric acid 10.62 265 467, 449, 287; hexose/ 450,
163 dihydrokaempferol hexose mixture 12 p-Coumaric acid/ 11 285
367, 344, 163, 147 caffeic acid conjugate, glycosylated 13 Femlic
acid 11 285, 315 sh 379, 196, 177 glycoside 14 Chlorogenic acid
12.77 325, 300sh 163, 377 Phenolic ester 15 p-Coumaric acid 11.55
275 396, 196, 163 derivatives derivative 16 Caffeoyl-quinic 14.96
310 acid dimer #1 17 Caffeoyl-quinic 26.63 573, 814, 163 acid dimer
#2 Phenolic 18 Caffeic acid 13.39 325, 295 sh 163 acids 19
p-coumaric acid 18.19 235, 310 165, 147, 119 20 Benzoic acid 22.36
21 Ferulic acid 22.61 177 22 Cinnamic acid 30.27 273 621, 599.5,
131.1 Flavonoid 23 Quercetin-3-O- 23.57 275 400, 303 glycosides
glycoside 24 Kaempferol 24.7 592, 535 glycoside 25 Quercetin-3-O-
25.44 765, 453, 303 trisaccharides 26 Naringin 25.88 285, 330 621,
563 27 Rutin 27.2 260, 350 633, 303 Flavonoid 28 Flavonoid 24.33
258 ester conjugate derivatives 29 Trace 27.5-30.0 Mixture
flavonoids + glycosides Flavonoids 30 Quercetin 36.5 255, 370 629,
303, 273 31 Kaempferol 44.58 260, 370 287 32 Naringenin 35.1
[0241] Table 4 provides IC50 data (for inhibiting platelet
aggregation) for the 32 compounds identified in the tomato extract.
Activity was assayed as described in Method 1.1.4. FIG. 1 provides
examples of dose-response curves of % inhibition of ADP-mediated
aggregation versus inhibitor solution concentration generated for
(a) a nucleoside (cytidine); (b) a nucleotide (adenosine 3'
monophosphate; (c) a phenolic acid glycoside (Caffeic acid
glucoside); (d) a phenolic acid (Caffeic acid); (e) a flavonoid
glycoside (Quercetin-3-O-glycoside); and (f) a flavonoid
(Quercetin).
TABLE-US-00004 TABLE 4 Antiplatelet Activity of Compounds
identified in Fruit Extracts Compound Bioactive IC50 IC50 Group ID
Compound IC50 ADP Collagen TRAP IC50 AA Nucleosides 1 Cytidine 2.42
10.66 39.03 39.03 2 Adenosine 0.4 0.82 >50 -- 3 Uridine 6.51
15.99 >50 -- 4 Guanosine 0.25 0.53 26.07 0.91 Nucleotides 5
Adenosine 3'- 0.12 0.28 24.51 2.41 monophospate 6 Adenosine 5'-
0.12 0.28 24.51 2.41 monophospate Phenolic acid 7 Mixed phenolic
N/A N/A N/A N/A glycosides acid glycosides 8 p-Coumaric acid 10.25
9.88 1.61 0.19 hexose/quinic acid derivative 9 Caffeic acid 10.16
8.22 0.8 0.23 glucoside 10 Femlic acid hexose 12.61 14.16 0.52 0.46
11 p-Coumaric acid 11.1 14 0.56 0.31 hexose/ dihydrokaempferol
hexose mixture 12 p-Coumaric acid/ 12.61 13.18 0.25 0.2 caffeic
acid conjugate, glycosylated 13 Ferulic acid 13.11 14.56 0.37 0.41
glycoside 14 Chlorogenic acid 10.08 10.11 1.1 0.77 Phenolic ester
15 p-Coumaric acid 14.65 15.18 0.35 0.26 derivatives derivative 16
Caffeoyl-quinic 31.55 35 11.12 0.3 acid dimer #1 17 Caffeoyl-quinic
32.96 33.07 12.16 0.2 acid dimer #2 Phenolic acids 18 Caffeic acid
18.98 11.37 8.03 7.33 19 p-coumaric acid 13.22 14.62 12.82 10.18 20
Benzoic acid 25.11 17.74 18.19 15.45 21 Ferulic acid 18.67 13.9
14.65 9.94 22 Cinnamic acid 22.14 24.6 12.92 0.22 Flavonoid 23
Quercetin-3-O- 25.18 28.43 12.06 0.19 glycosides glycoside 24
Kaempferol >50 >50 N/A N/A glycoside 25 Quercetin-3-O- >50
>50 18.61 0.46 trisaccharides 26 Naringin 28.1 29.55 9.13 0.31
27 Rutin 35.21 32.18 8.96 0.41 Flavonoid ester 28 Flavonoid 27.68
27.22 13.67 0.23 derivatives conjugate 29 Trace N/A N/A N/A N/A
flavonoids + glycosides Flavonoids 30 Quercetin >50 >50 19.66
3.66 31 Kaempferol >50 >50 26.18 5.18 32 Naringenin >50
>50 33.21 10.41
[0242] 1.3 CONCLUSIONS
[0243] The inventors tested a number of compound found within
tomato extracts and established that the 32 compounds identified in
tables 2 and 3 had efficacy for preventing platelet aggregation.
Furthermore they concluded that, of the 32 compounds isolated and
shown to have anti-aggregatory capacity, 16 of these compounds were
most important for overall bioactivity. These 16 compounds are
shown in Table 1.
[0244] In particular they were surprised to find that the bioactive
compounds could be grouped into (a) phenolic compounds (and ester
and glycoside derivatives thereof); (b) flavonoids (and ester and
glycoside derivatives thereof) and (c) nucleotides/nucleosides.
This lead them to realise that two new classes of compounds (the
phenolics and flavonoids) exist which have an inhibitory effect on
platelet aggregation.
[0245] Of these compounds, the most anti-aggregatory of the
non-phenolic compounds was AMP. Modification of the nucleoside by
sugar and phosphate residues had the effect of substantially
increasing the anti-aggregatory behaviour. This was surprising as
earlier work had identified cytidine and adenosine as antiplatelet
constituents, but no nucleotides.
[0246] Of the phenolic acid-derived compounds identified, the most
anti-aggregatory overall were the glycosylated forms of p-coumaric
and caffeic acids. These glycosylated compounds showed markedly
higher anti-aggregatory potential in response to all agonists
tested, compared to the non-glycosylated free acids. This is the
first time such a structure-function relationship has been
reported. Accordingly glycosylated phenolic compounds represent
most preferred bioactive molecules that may be contained with the
extracts according to the invention and which should be
maintained/enriched in extracts prepared according to the method of
first aspect of the invention.
[0247] A similar finding was made with regard to the flavonoid
derivatives. The glycosides or other conjugated derivatives of
quercetin and naringenin were markedly more anti-aggregatory than
the flavonoid aglycones. This was particularly noticeable in
response to TRAP and arachidonic acid agonists, but also applied to
ADP and collagen agonists. While a (very limited) amount of
structure-function studies have been reported in the literature for
the free flavonoid aglycones, the authors are unaware of any
studies comparing aglycones and conjugated molecules.
[0248] Accordingly glycosylated flavonoid compounds also represent
most preferred bioactive molecules that may be contained with the
extracts according to the invention and which should be
maintained/enriched in extracts prepared according to the method of
the first aspect of the invention.
[0249] It was interesting to note that when the ratio of AMP to
adenosine decreased, the overall bioactivity of the extract
decreased. The same was found to happen when the ratio of phenolic
acid glycosides/esters to free phenolic acids decreased, and when
the ratio of flavonoid glycosides to free flavonoids decreased.
[0250] It is worth noting that a simple way of producing a fruit
extract according to the third aspect of the invention is disclosed
in 1.1.3. An extract prepared according to the methods disclosed in
WO 99/55350 may be fractionated to isolate three fractions which
were identified as having anti-platelet activity. Fraction 1
contained largely nucleosides and nucleotides. Fraction 2 contained
largely phenolic acid glycosides/esters, and phenolic acids.
Fraction 3 contained largely flavonoid glycosides and flavonoids.
These three fractions can then be recombined (fraction 1+2+3) to
provide an extract according to the third aspect of the invention
which has surprising efficacy.
EXAMPLE 2
[0251] In view of the knowledge gained with regards active
compounds within tomato extracts. The inventors proceeded to
develop methods of processing fruits to produce extracts in which
the activity of the compounds was maintained and/or in which the
concentration of such active compounds was enriched.
[0252] After much experimentation the inventors established that
the methodology according to the first aspect of the invention was
optimal for producing extracts enriched in a significant number of
the active compounds identified in Example 1.
[0253] Having established this methodology the inventors went on to
develop a process that could be used in the industrial scale-up of
the methods of the invention to produce a syrup that may be used in
the manufacture of pharmaceutical or food products (drinks or food
stuffs).
[0254] The process for making such a syrup is illustrated in FIG. 2
and represents a preferred embodiment of the first aspect of the
invention.
[0255] Syrups prepared according to the process of FIG. 2 represent
a most preferred extract according to the second or third aspect of
the invention and have the properties defined in Table 2 (see
above) and also Table 5.
TABLE-US-00005 TABLE 5 Composition of a most preferred Tomato
Extract according to the second or third aspects of the invention.
Specification Parameter Specification Dry Matter (.degree.Brix) 60
to 63 Density (g/cm.sup.3) 1.15 to 1.22 pH (at 4.degree.Brix) 3.90
to 4.15 Browning index (at 4.degree.Brix) <0.70 Total
Carbohydrates (g/100 g) 58 to 70 Pectin (g/100 g) 33 to 40 Reducing
Sugars (g/100 g) 22 to 30 Protein (g/100 g) 4 to 6 Free Amino Acids
(g/100 g) .sup. 2 to 3.5 Bioactive compounds (g/100 g) 3.0 to 4.0
Total viable count (CFU/mL) <1,000 Salmonella (CFU/25 mL) Absent
Listeria monocytogoenes Absent (CFU/25 mL) Staphylococcus aureus
Absent (CFU/mL) Enterobacteria (CFU/mL) <10 Yeasts and molds
(CFU/mL) <1,000
[0256] The syrup may contain up to 70% dry matter simple sugars
(glucose, fructose and sucrose) and may contain up to 50%
water.
[0257] Most preferred Syrups produced using this method contain up
to 32 bioactive components, which are numbered in the HPLC
chromatogram shown in FIG. 3 and correspond to the numbered
compounds identified in Table 1-4 and discussed in Example 1.
[0258] Some additional characteristics of the syrups, which are
important in optimising their bioactivity profile, are provided in
table 6 (below). Compound numbers refer to the chromatogram shown
in FIG. 3 and the compounds identified in Table 1-4.
TABLE-US-00006 TABLE 6 Compound ID Specification Compounds 2-6
>2.00 mg/g Compound 8 >0.05 mg/g Compound 9 >0.07 mg/g
Compound 10 >0.03 mg/g Compound 11 >0.30 mg/g Compound 12
>0.20 mg/g Compound 13 >0.16 mg/g Compound 14 >0.13 mg/g
Compound 15 >0.10 mg/g Compound 23 >0.05 mg/g Compound 25
>0.16 mg/g Compound 26 >0.74 mg/g Compound 27 >0.60 mg/g
Compounds 18, 19 & 21 <1.50 mg/g Compound 5: >3.0
Compound 2 ratio Glutamine >8.00 mg/g Furfural derivatives
<0.15 mg/g
[0259] The inventors recognised that the characteristics outlined
in Table 6 were important when optimising anti-platelet activity of
extracts according to the invention. Most preferred extracts
according to the second or third aspects of the invention have
these properties. Furthermore these characteristics can be used as
Quality control measures in most preferred embodiments of the
methods of the first aspect of the invention. Therefore these
characteristics are particularly useful control point when extracts
are produced on an industrial scale.
EXAMPLE 3
[0260] The inventors also developed a process that could be used in
the industrial scale-up of the methods of the invention for the
production of a low-sugar fruit extract in the form of a powder.
The powder may also be used in the manufacture of pharmaceutical or
food products (drinks or food stuffs).
[0261] A process for producing such a powder is illustrated in FIG.
4 and represents a preferred embodiment of the first aspect of the
invention.
[0262] Extracts prepared according to the process of FIG. 4 also
represent preferred extracts according to the second or third
aspect.
[0263] Extracts prepared according to the process of FIG. 4
represent a preferred extract according to the second or third
aspect of the invention and have the properties defined in Table 2
(see above) and also Table 7.
TABLE-US-00007 TABLE 7 Composition of a most preferred low sugar
Tomato Extract according to the second or third aspects of the
invention Specification Parameter Specification Dry Matter (% w/w)
94 to 96 Bulk density (g/cm.sup.3) 0.25 to 0.30 PH (in water at
4.degree.Brix) 3.5 to 3.8 Browning index (in water <3.00 at
4.degree.Brix) Total Carbohydrates (g/100 g) <0.1 Pectin (g/100
g) -- Reducing Sugars (g/100 g) <0.1 Protein (g/100 g) <0.01
Free Amino Acids (g/100 g) 30 to 37 Bioactive compounds (g/100 g)
50 to 60 Total viable count (CFU/mL) <1,000 Salmonella (CFU/25
mL) Absent Listeria monocytogoenes Absent (CFU/25 mL)
Staphylococcus aureus Absent (CFU/mL) Enterobacteria (CFU/mL)
<10 Yeasts and molds (CFU/mL) <1,000
[0264] The powder may contain less than 1% dry matter simple sugars
(glucose, fructose and sucrose) and may contain <6% water. The
enriched powder extract typically contains up to 60% bioactive
compounds.
[0265] Extracts produced using this method also contain up to 33
different bioactive components, which are numbered in the HPLC
chromatogram shown in FIG. 5 and correspond to the numbered
compounds identified in Tables 1-4 and as discussed in Example
1.
[0266] Some additional characteristics of these powders, which are
important in optimising their bioactivity profile, are given in
Table 8. Compound numbers refer to the chromatogram shown in FIG. 5
and tables 1-4.
TABLE-US-00008 TABLE 8 Compound ID Specification Compounds 2-6
>15.20 mg/g Compound 8 >9.40 mg/g Compound 9 >3.70 mg/g
Compound 10 >0.70 mg/g Compound 11 >26.10 mg/g Compound 12
>90.80 mg/g Compound 13 >85.30 mg/g Compound 14 >18.30
mg/g Compound 15 >8.60 mg/g Compound 23 >8.50 mg/g Compound
25 >14.70 mg/g Compound 26 >38.00 mg/g Compound 27 >50.70
mg/g Compounds 18, 19 & 21 <38.00 mg/g Compound 1: >3.0
Compound 3 ratio Glutamine >52.00 mg/g Furfural derivatives
<0.50 mg/g
[0267] The inventors recognised that the characteristics outlined
in Table 8 were important when optimising anti-platelet activity of
extracts according to the invention. Most preferred extracts
according to the second or third aspects of the invention have
these properties. Furthermore these characteristics can be used as
Quality control measures in most preferred embodiments of the
methods of the first aspect of the invention. Therefore these
characteristics are particularly useful control point when extracts
are produced on an industrial scale.
EXAMPLE 4
[0268] In the following Example, an experiment is described in
which the anti-platelet efficacy of a composition prepared
according to the methods described in Example 2 was tested. It will
be appreciated that compositions prepared according the methods
described in Example 3 could be tested following the same
protocol.
[0269] 4.1 Study Protocol
[0270] 4.1.1 Study Objectives and Short Outline
[0271] This study Quantified the ex vivo antiplatelet effect of
consuming a treatment drink containing 3 g of tomato extract syrup
(prepared according to the methods described in Example 2),
compared to a control supplement, in healthy subjects.
[0272] 4.1.2 Study Design
[0273] A single-blinded study design was followed. Fasted subjects
were cannulated and a baseline sample was taken between 07:00 and
08:00. Directly after collection of the baseline sample, subjects
consumed either a treatment (TE) or a control supplement. Further
blood samples were then withdrawn from the cannula at time t=3
hours. Subjects were offered small volumes (25 mL) of water between
sampling time points to avoid dehydration.
[0274] 4.1.3 Subjects
[0275] 9 healthy adults of both sexes were recruited into the
study. Subjects were aged 40-65 years, with no medical history of
serious disease or hemostatic disorders. Suitability for inclusion
onto the study was assessed by diet and lifestyle questionnaires
and medical screening, during which a full blood count was
obtained. Individuals with low hematology counts were not included
in the study. Any subjects habitually consuming dietary supplements
(e.g. fish oils, evening primrose oil) suspended these supplements
for a minimum period of one month before participating in the
study. Subjects were instructed to abstain from consuming drugs
known to affect platelet function for a 10-day period prior to
participation. Written informed consent was obtained from all
subjects, and the study was approved by Grampian Research Ethics
Committee.
[0276] 4.1.4 Phlebotomy
[0277] Subjects recruited into the study were cannulated using a
siliconized 21-gauge butterfly needle, to cause minimum disruption
to the vein while taking multiple blood samples. To minimize
activation of the hemostatic system, a maximum of three
venepunctures was specified. The cannula remained in place over the
entire study time period, and venous blood samples of .about.30 mL
were withdrawn at each sampling timepoint, discarding the first 2
mL on each occasion. After blood sample collection, the cannula was
flushed with saline to prevent blockage. For measurements of
platelet function and clotting time, blood was collected into
plastic syringes and transferred into citrated blood collection
tubes (final concentration sodium citrate, 13 mmol/L). For
measurement of C-reactive protein (CRP), a single baseline blood
sample (5 mL) was taken into EDTA anticoagulant (final
concentration, 1.6 g/L). For measurement of fibrinopeptide A at
each timepoint, 4.5 mL blood was collected into 0.5 mL of a mixed
anticoagulant containing EDTA, trasylol and chloromethylketone.
Blood samples were incubated at 37.degree. C. in a portable
incubator for transfer to the laboratory. Any blood samples showing
evidence of activation, defined as a fibrinopeptide A concentration
higher than 6 .mu.g/L, were discarded. Any volunteers showing
evidence of an elevated inflammatory response, as evidenced by a
baseline C-reactive protein concentration higher than 6 mg/L, were
withdrawn from the study for the period affected, and the scheduled
intervention was undertaken at a later date.
[0278] 4.1.5 Ex Vivo Platelet Aggregation Studies
[0279] Measurement of the extent of ADP and collagen-induced
platelet aggregation in platelet-rich plasma was carried out at
each timepoint. Different agonist concentrations may be used to
approximate different physiological conditions. In order to collect
data under conditions of suboptimal platelet stimulation, a
standardized lower concentration (3 .mu.mol/L for ADP, 3 mg/L for
collagen) was defined as suboptimal, while a standardised upper
concentration (7.5 .mu.mol/L for ADP, 5 mg/L for collagen) was
defined as optimal. These agonist concentrations were used for all
measurements. Effects on platelet aggregation observed after
treatment or control interventions are expressed as the percentage
change in area under the aggregation curve after consumption of
extract/placebo, compared to baseline values.
[0280] 4.1.6 Supplementary Measurements
[0281] Detection of high plasma CRP was carried out using a
semi-quantitative latex agglutination assay (Dade Behring, UK),
which detected levels in plasma >6 mg/L. This threshold is taken
as an indication of acute inflammatory system activation, such as
may be associated with infection (e.g. onset of a viral infection
or a cold) or injury (e.g. tendonitis). Samples displaying signs of
such acute activation should not be used for platelet function
studies.
[0282] Measurement of FPA was carried out by ELISA (Zymutest FPA
assay, HyphenBioMed, France), on plasma from which fibrinogen had
been removed by bentonite adsorption treatments. Presence of FPA in
plasma at levels greater than 6 .mu.g/L was taken as an indication
of haemostatic system activation during blood sampling. Such
samples should not be used for platelet function measurement as
results obtained will not be reliable. Thus circulating CRP levels
and blood sample FPA levels were used to indicate suitability of
samples for platelet measurements.
[0283] 4.2 Results
[0284] No blood samples drawn during this study displayed levels of
circulating CRP higher than the threshold 6 mg/L, indicating that
acute phase activation was not present in any subject during the
study sampling days. Similarly, in blood samples drawn for this
study, no samples showed FPA levels higher than the threshold 6
.mu.g/L. Thus all blood samples received were judged suitable for
platelet function studies. This screening data is not included.
[0285] The data presented in FIG. 6 illustrate platelet aggregation
measurements carried out at baseline (t=0) and at 3 hours
post-consumption of treatment supplements (t=3). Results are
expressed as % inhibition of platelet aggregability, compared to
baseline values.
[0286] 4.3 Conclusions
[0287] FIG. 6 demonstrates that tomato extracts according to the
invention result in a reduction from baseline platelet aggregation
of between 18% and 28% for ADP mediated aggregation, and between 3%
and 12% for collagen mediated aggregation, 3 hours after
consumption. Consumption of the control supplement resulted in a
change from baseline aggregation of between 2% and 4% for
ADP-mediated aggregation, and approximately 2% for
collagen-mediated aggregation, after 3 hours. The differences
between baseline and 3-hour time points were not significant for
the control supplement, but were significant at P <0.001 for the
tomato extract supplement. Differences between the control and
tomato extract supplements were also significant at the P <0.001
level.
[0288] These results clearly demonstrate that tomato extracts
according to the invention are useful for treating conditions
characterised by inappropriate platelet aggregation.
[0289] Furthermore the inventors have established that the methods
according to the invention result in the production new tomato
extracts with improved properties when compared to known tomato
extracts (e.g. those disclosed in WO 99/55350). The inventors
compared ex vivo antiplatelet activity measured after eating tomato
extract produced by known processing method, and tomato extract
produced using the methods according to the present invention which
target maintenance of glycosides and esters. They found that a
single dose of 3 g of tomato extract according to the present
invention resulted in an inhibition of 3 .mu.mol/L ADP-induced
platelet aggregation of 28% compared to baseline whereas, known
extracts result in an inhibition of ADP-induced platelet
aggregation of .about.25% although this is only achieved by
consuming 9 g of extract. Thus the methods of the present invention
appear to enrich bioactives in the extract by approximately 3
times. According employment of the methods of the first aspect of
the invention result in a more potent extract and, advantageously,
the necessary daily dose may be reduced.
EXAMPLE 5
[0290] The inventors prepared a number of products that represent
preferred formulations comprising extracts according to the
invention.
[0291] Yoghurt Drinks Containing Tomato Extracts
[0292] The tomato extracts prepared as described in Examples 2 and
3 are both suitable for incorporation into a yoghurt drink. An
example of such a drink may be prepared as follows.
[0293] Drinking yoghurt, formulated without live probiotic
cultures, should be pre-pasteurised and cooled to 4-8.degree. C.
The cooled yoghurt should be mixed with tomato extract as prepared
in Example 2 in the ratio 50:1, or with tomato extract as prepared
in Example 3 in the ratio 1000:1 (w/w). Acidity should be checked
and regulated with citric acid, and flavouring should be adjusted.
If a probiotic culture is required in the final product, this
should be added after adjustment, and the final mixture should be
packaged into single-serve 150 g bottles.
[0294] Each single-serve 150 g bottle should then contain either 3
g tomato extract prepared according to Example 2, or 150 mg tomato
extract prepared according to Example 3. This represents a single
daily dose. The final products should be stored at 4.degree. C. for
their recommended shelf life (typically between 14 and 21
days).
[0295] Fat Spreads Containing Tomato Extract
[0296] Tomato extract prepared as described in Example 3, or
further processed to give an encapsulate, is suitable for
incorporation into fat spreads. An example of such a formulation
may be produced by post-pasteurisation dosing the powdered,
low-sugar tomato extract into pre-formulated, pasteurised and
cooled fat spread in the ratio 200:1 (w/w). The mixture should be
homogenised at high shear to ensure homogenous distribution, and
packaged into multi-serve containers.
[0297] Label text should include the information that the normal
daily intake of fat spread should be approximately 30 g.
Consumption of 30 g fat spread per day will result in a daily
intake of approximately 150 mg tomato extract, which constitutes a
single daily dose. The spread should be stored at 4.degree. C. for
the duration of its shelf life (typically 90 days).
[0298] Fruit Juice-Based Drinks Containing Tomato Extracts
[0299] The tomato extracts prepared as described in Examples 2 and
3 are both suitable for incorporation into a fruit-juice based
drinks. An example of such a drink may be prepared as follows.
[0300] Dilute orange juice concentrate with water in the ratio
1:5.4. To the reconstituted juice, add 0.1% grapefruit flavour,
0.05% pineapple flavour, and 1.2% tomato extract as produced in
Example 2. Test acidity and sweetness, and add up to 5% citric acid
(acidity regulator) and up to 2% sucralose, as required. Pasteurise
for 90 seconds at 121.degree. C.
[0301] Package the pasteurised mixture in 1 L cartons, or in
single-serve cartons or bottles. 250 mL of the final drink as
described should contain approximately 3 g tomato extract,
equivalent to a single daily dose. Label details should contain
this information and the advice to drink one 250 mL portion per
day.
[0302] Other fruit juice concentrates are equally appropriate for
use; alternatively fresh fruit juices, mixtures of fruit and
vegetable juices, or mixtures containing variable amounts of pulp,
may be prepared.
[0303] Encapsulates
[0304] Prepare a 50% w/w solution of powdered, low-sugar tomato
extract which has been manufactured as described in Example 3.
Raise the temperature to 60.degree. C. Mix with an equal volume of
either: a melted and emulsified mixture of high-melting fats, e.g.
triglycerides; a solution of dispersed polysaccharides, e.g.
pectins, agars; or other suitable polymers. Homogenise with care to
ensure correct blending. Produce an encapsulate using a technique
such as temperature-controlled spray-drying, controlling particle
size so that final particle size is <200.mu.. Additives such as
colours, preservatives or free-flow agents may be added to the
dispersion prior to spray drying, as appropriate.
[0305] The resulting encapsulate should contain between 12% and 20%
tomato extract on a w/w basis. The encapsulate should be stored at
<4.degree. C., in the dark, in sealed foil wrapping materials.
Dosage of the encapsulate should be in the range 400 mg-700 mg per
day, when incorporated into food products.
[0306] Sacheted Ready-to-Dissolve Formulations
[0307] The tomato extract as described in Example 3 is suitable for
incorporation into pre-mixed, ready-to-dissolve single serving
sachet formulations. An example of such a formulation may be
prepared by mixing: 150 mg powdered, low-sugar tomato extract; 285
g maltodextrin; 6.5 g strawberry cream flavour; 0.8 g sucralose;
3.8 g citric acid; 2.5 g natural beet red colour; and 0.25 g
caramel. The resulting .about.300 g dry powder mix can be presented
in a single-serve foil-backed sachet, suitable for dissolving in
between 50 mL and 300 mL water, to taste. Each 300 g mixture
contains a single daily dose of tomato extract.
[0308] The powdered, sacheted formulation should be stored at room
temperature, and presented with instructions to consume one sachet
per day in water.
[0309] Tablets
[0310] The tomato extract as described in Example 2 may used to
prepare tablets for pharmaceutical or dietary supplement use, e.g.
tabletting by direct compression, as follows.
[0311] The tomato extract as described in Example 2 should be
milled/ground to a particle size range of 1-3.mu. prior to
tabletting. The pre-ground powdered extract should be dry-blended
with an excipient such as microcrystalline cellulose, or
maltodextrin M700, to provide lubrication during the compression
process. A ratio of 40% extract to 60% excipient is suitable, but
ratios from 10:90 to 60:40 may also be used. Powdered colourants
may also be added as required.
[0312] Using a conventional tabletting machine, set at a pressure
of 1.5-2.0 tonnes/square inch, 212 g tablets of 5 kg hardness may
be produced. Such tablets will contain 85 mg tomato extract per
tablet. Storage in laminated aluminium foil blister packs is
recommended. In such packaging, tablets will be stable to storage
under temperatures up to 45 C. Two tablets should be taken
together, once or twice per day, to achieve a recommended dosage
level.
EXAMPLE 6
[0313] In Example 4 the direct antiplatelet effects of a
composition prepared according to the methods described in Example
2 were described. To illustrate that these antiplatelet effects are
of a magnitude to affect blood fluidity or blood flow, further work
was undertaken in which the effects of this composition on overall
primary haemostasis was measured. Haemostasis, that is, the halting
of bleeding by the clotting process, occurs in two parts. Primary
haemostasis refers to the ability of whole blood to form platelet
micro- and macro-aggregates under flowing conditions, and form an
initial platelet clot on a collagen-rich surface (normally a blood
vessel wall). Secondary haemostasis refers to the formation of a
fibrin network in this primary clot, induced by thrombin, which
leads to a more permanent clot which takes significant time to
dissolve via fibrinolysis. Measurement of primary haemostasis gives
data that may be more physiologically relevant than aggregation
data alone, when examining the efficacy of the tomato extract
composition in affecting blood fluidity and thus blood flow.
[0314] In the following Example, an experiment is described in
which the effect on overall primary haemostasis of a composition
prepared according to the methods described in Example 2 was
tested, using a Platelet Function Analyser, the PFA-100.RTM.. The
platelet function analyzer device has become a useful tool for
measurement of primary hemostasis in small samples of blood. This
test system is a microprocessor controlled instrument which
emulates in vitro the platelet dependent phase of primary
hemostasis, while delimiting the role of the rheological factors.
Basically, the system monitors platelet interaction on collagen-ADP
(COL-ADP) or collagen-epinephrine (COL-EPI) coated membranes.
Samples of citrated blood are aspirated under controlled flow
conditions (shear rate: 4,000-5,000/s) through a 150-micrometer
aperture cut into the membrane. During the process, the growing
platelet plug progressively blocks the blood flow through the
aperture cut. The platelet hemostatic capacity in the blood sample
is indicated by the time required for the platelet plug to occlude
the aperture (closure time), which is expressed in seconds.
[0315] 6.1 Study Protocol
[0316] 6.1.1 Study Objectives and Short Outline
[0317] This study examined the ex vivo effect of consuming 3 g of
tomato extract syrup (prepared according to the methods described
in Example 2), compared to a control supplement, on primary
haemostasis in healthy subjects.
[0318] 6.1.2 Study Design
[0319] 6 healthy adults aged 45-75 years, with normal hemostatic
parameters (blood counts), no medical history of serious disease or
hemostatic disorders, and not consuming dietary supplements or
drugs known to affect platelet function, were recruited. Written
informed consent was obtained, and the study was approved by
Grampian Research Ethics Committee. Baseline blood samples
(anticoagulated with acid citrate dextrose buffer) were taken from
fasted subjects between 07:00 and 08:30. Directly after collection
of the baseline sample, subjects consumed either a treatment (TE)
or a control supplement. Further blood samples were then taken at
time t=3 hours, and t=5 hours after supplementation.
[0320] 6.1.5 Ex Vivo Measurement of Primary Haemostasis
[0321] Measurement of PFA-1 00 closure time in whole blood samples
was carried out at each timepoint. Measurements were carried out
using collagen-epinephrine membranes. Briefly, cartridges
containing the appropriate membranes were brought to room
temperature, and 900 tJI of anticoagulated whole blood was inserted
into the reservoir of each cartridge. The cartridges were then
immediately inserted into the processing unit of the PFA-100. The
blood was aspirated automatically from the reservoir through the
cartridge membrane at high shear, until the membrane aperture was
closed (closure time) or for a maximum of 300 s in the event that
no clot was formed. Closure times were recorded and a printout
produced. All measurements were carried out a minimum of 30 minutes
after blood sampling.
[0322] 6.2 Results
[0323] Average closure times for each treatment are presented
graphically in FIG. 7. In this Figure recorded average closure
times are shown for the baseline (time 0 relative to
supplementation with treatment (TE) or control (C)), and at 3 hours
and 5 hours after supplementation with TE or C. n=3 for each group,
and data were analysed by ANOVA. Significant differences between C
and TE are indicated on the graph by * (P=0.011).
[0324] 6.3 Conclusions
[0325] Results demonstrate that tomato extracts representing
compositions according to the invention result in an average
increase in PFA-100 closure time of 24% from baseline values, 3 and
5 hours after consumption. Consumption of the control supplement
resulted in an average decrease from baseline closure times of 16%
after 3 hours, and 12% after 5 hours. The differences between
baseline and 3 and 5-hour time points were not significant for the
control supplement, but were significant at P=0.011 for the tomato
extract supplement. Differences between the control and tomato
extract supplements were significant (P=0.011).
[0326] The results show that the tomato extract supplement
compositions in accordance with the invention increase the time
taken for a platelet clot to form in each cartridge aperture,
implying that the platelet hemostatic potential has decreased. The
longer time required for a clot to form reflects a higher blood
fluidity.
[0327] These results clearly demonstrate that compositions (such as
tomato extracts) according to the invention are useful in reducing
blood fluidity. This supports their use in normalising blood
flow.
* * * * *